EyePoint Pharmaceuticals
EyePoint is a clinical-stage biopharmaceutical company developing sustained-release ophthalmic therapeutics using its proprietary Durasert E™ platform, with lead asset DURAVYU in Phase 3 trials for wet AMD and diabetic macular edema, plus two FDA-approved commercial products, YUTIQ and DEXYCU.
- Company typePublic
- Founded2008
- HeadquartersWatertown, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What EyePoint Pharmaceuticals does
EyePoint Pharmaceuticals (now operating as EyePoint, Inc.) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts that develops sustained-release therapeutics for serious retinal diseases. The company's core technology is the proprietary Durasert E™ bio-erodible delivery platform, which enables sustained intraocular drug release over approximately six months per dose; this platform has been validated through four FDA-approved products, and EyePoint currently markets two of them commercially: YUTIQ, a three-year intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a single-dose steroid for post-cataract inflammation. Lead pipeline asset DURAVYU (vorolanib intravitreal insert) combines a multi-mechanism tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 with the Durasert E platform, and is currently in Phase 3 trials for wet age-related macular degeneration (LUGANO) and diabetic macular edema (COMO and CAPRI).
The company's commercial business model today is small and declining, with FY2025 revenue of $31.4 million driven largely by deferred revenue recognition from a 2023 YUTIQ licensing agreement, and an annualized run rate that has dropped below $5 million as that deferred revenue winds down. Pricing for the investigational DURAVYU has not been publicly disclosed, and the company has historically supplemented product sales with royalty arrangements, including a March 2025 transaction that sold a 3.125% perpetual royalty on YUTIQ and ILUVIEN net revenues to SWK Funding for $17.25 million. EyePoint has raised approximately $172.5 million in oversubscribed public equity financing in October 2025, holds roughly $300-306 million in cash extending runway into Q4 2027, and is investing in commercial readiness through executive hires (including a Chief Commercial Officer recruited from the Genentech Lucentis launch team) and manufacturing scale-up at its Northbridge, MA facility.
EyePoint Pharmaceuticals firmographics
Firmographics- Name
- EyePoint Pharmaceuticals
- Legal name
- EyePoint, Inc.
- Website
- https://eyepointpharma.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- EyePoint is a clinical-stage biopharmaceutical company developing sustained-release ophthalmic therapeutics using its proprietary Durasert E™ platform, with lead asset DURAVYU in Phase 3 trials for wet AMD and diabetic macular edema, plus two FDA-approved commercial products, YUTIQ and DEXYCU.
- Ownership category
- akta.pro rank
EyePoint Pharmaceuticals industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals (Retinal Disease Therapeutics)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where EyePoint Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EyePoint Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Product Sales (Commercialized Drugs): Revenue generated from FDA-approved products YUTIQ and DEXYCU. YUTIQ is an intravitreal implant for chronic non-infectious uveitis, and DEXYCU is for postoperative inflammation following cataract surgery. Revenue has been declining, with Q3 2025 revenue of $1.0 million down from $10.5 million in Q3 2024 primarily due to recognition of remaining deferred revenue from 2023 YUTIQ licensing agreement.
- Licensing Royalties: EyePoint has historically received royalty payments from licensing agreements, including the 2023 YUTIQ licensing agreement that contributed to prior year revenue recognition. The company sold a 3.125% perpetual royalty obligation on YUTIQ and ILUVIEN net revenues to SWK Funding LLC for USD 17.25 million in March 2025.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
EyePoint Pharmaceuticals product offering
Product offeringCore offering
EyePoint Pharmaceuticals is a clinical-stage and commercial biopharmaceutical company developing and selling sustained-release ophthalmic therapeutics for serious retinal and ocular diseases. Its lead investigational product, DURAVYU, combines the tyrosine kinase inhibitor vorolanib with the proprietary Durasert E bioerodible delivery technology for intravitreal treatment of diabetic macular edema, wet AMD, and retinal vein occlusion. Commercial offerings include YUTIQ, a 0.18 mg fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a 9% dexamethasone suspension for postoperative inflammation following cataract surgery.
Product overview
EyePoint is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious retinal diseases. The company's portfolio consists of its lead investigational product DURAVYU (vorolanib intravitreal insert) in Phase 3 trials for wet AMD and diabetic macular edema, two FDA-approved commercial products (YUTIQ and DEXYCU), and a proprietary Durasert drug delivery technology platform that has supported four FDA-approved products. The Durasert technology enables sustained intraocular delivery of therapeutic agents, with DURAVYU specifically utilizing the next-generation Durasert E platform to provide approximately six-month dosing compared to standard anti-VEGF injections that require dosing every few weeks.
Differentiator
Problem solved
Functional benefit
Brands
- DURAVYU: Lead investigational product candidate - sustained-release tyrosine kinase inhibitor (TKI) for serious retinal diseases, combining vorolanib with Durasert E technology
- Durasert E
- Durasert
Products and services
- DURAVYU (vorolanib in Durasert E)
Quantifiable outcome
- Over 80% reduction in treatment burden compared to standard aflibercept injections in Phase 2 trials
- +2 more outcomes
Companies that use EyePoint Pharmaceuticals
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
EyePoint Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
EyePoint Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- American College of Eye Technicians (ACET)minorEyePoint is one of several pharmaceutical companies (including Alcon, Bausch + Lomb, Dompe, RxSight, and Topcon Healthcare) subsidizing training costs for ACET's 8-week virtual ophthalmic technician training program to address workforce shortages in the ophthalmology field.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
EyePoint Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Astellas Pharma (IVERIC bio): Acquired IVERIC bio for Izervay (avacincaptad pegol), a complement inhibitor for geographic atrophy. Comparable as a recently launched ophthalmology biopharma targeting retinal disease.
- Novartis: Markets Beovu (brolucizumab) for wet AMD, a competing anti-VEGF therapy in the same retinal disease space where DURAVYU is being developed.
- Roche / Genentech: Markets Lucentis and Vabysmo for wet AMD and DME. Vabysmo's extended dosing interval is the closest direct competitor to DURAVYU's 6-month sustained-release proposition.
- Regeneron Pharmaceuticals: Develops and markets Eylea and Eylea HD, the leading anti-VEGF therapies for wet AMD and DME. Most directly comparable as the dominant incumbent in the same indications DURAVYU targets.
- Apellis Pharmaceuticals: Develops Syfovre for geographic atrophy and is a clinical-stage ophthalmology peer with similar development-stage dynamics and focus on retinal disease therapeutics.
Emerging players
- Outlook Therapeutics: Developing ONS-5010 / Lytenava, an ophthalmic formulation of bevacizumab for wet AMD. Comparable as a late-stage ophthalmology biopharma pursuing wet AMD market entry.
- Clearside Biomedical: Develops suprachoroidal delivery-based therapies for retinal diseases including XIPERE for macular edema. Comparable on novel intraocular drug delivery and ophthalmology specialty focus.
- Adverum Biotechnologies: Developing gene therapies (ADVM-022 / ixoberogene soroparvovec) for wet AMD with the goal of reducing injection frequency. Closely comparable on the sustained-release / reduced-burden value proposition.
- Opthea: Clinical-stage biotech developing OPT-302 for wet AMD. Highly comparable as a small-cap ophthalmology biotech with Michael Campbell previously serving as COO.
- Kodiak Sciences: Clinical-stage biotech developing antibody biopolymer conjugates for retinal vascular diseases including wet AMD. Comparable as a retinal-focused biotech with similar development-stage risk profile.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
EyePoint Pharmaceuticals social profiles
Digital presenceEyePoint Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
EyePoint Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles14 records
EyePoint Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds11 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EyePoint Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EyePoint Pharmaceuticals
What does EyePoint Pharmaceuticals do?
EyePoint Pharmaceuticals is a clinical-stage and commercial biopharmaceutical company developing and selling sustained-release ophthalmic therapeutics for serious retinal and ocular diseases. Its lead investigational product, DURAVYU, combines the tyrosine kinase inhibitor vorolanib with the proprietary Durasert E bioerodible delivery technology for intravitreal treatment of diabetic macular edema, wet AMD, and retinal vein occlusion. Commercial offerings include YUTIQ, a 0.18 mg fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, and DEXYCU, a 9% dexamethasone suspension for postoperative inflammation following cataract surgery.
Is EyePoint Pharmaceuticals a public or private company?
EyePoint Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was EyePoint Pharmaceuticals founded?
EyePoint Pharmaceuticals was founded in 2008. It employs 101 to 250 people.
Where is EyePoint Pharmaceuticals based?
EyePoint Pharmaceuticals is headquartered in Watertown, United States, in the North America region.
How does EyePoint Pharmaceuticals make money?
Two revenue lines are on record. Product Sales (Commercialized Drugs) is the primary driver. The others are licensing Royalties.
Who are EyePoint Pharmaceuticals's main competitors?
Direct peers on record are Astellas Pharma (IVERIC bio), Novartis, Roche / Genentech, Regeneron Pharmaceuticals and Apellis Pharmaceuticals. Emerging players are Outlook Therapeutics, Clearside Biomedical, Adverum Biotechnologies, Opthea and Kodiak Sciences.
Does EyePoint Pharmaceuticals have an API?
No public API is recorded for EyePoint Pharmaceuticals.
What industry is EyePoint Pharmaceuticals in?
EyePoint Pharmaceuticals's product category is Ophthalmic Pharmaceuticals (Retinal Disease Therapeutics). Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.